# Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer

> **NCT05572476** · PHASE2 · WITHDRAWN · sponsor: **Institut Bergonié**

## Conditions studied

- Small Cell Lung Cancer
- Platinum-Sensitive Lung Small Cell Carcinoma
- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Association of lurbinectedin and durvalumab
- **DRUG:** Association of carboplatin and etoposide

## Key facts

- **NCT ID:** NCT05572476
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment difficulties, decline in the incidence of the studied pathology, active competitive clinical trials
- **Last updated:** 2024-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572476, "Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05572476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*